Join me & keynote speaker Dr. Florian Rieder at #CCCongress26, Jan. 22-24 in Vegas. @ibd-flomd.bsky.social does an outstanding job bridging #IBD basic science and clinical research, so this is sure to be a great talk Register by 10/21 & SAVE: 🔗 bit.ly/4m85s1N
#IBDsky #GIsky #Gastrosky
#IBDsky #GIsky #Gastrosky
Home 2026
Join colleagues across the entire spectrum of clinical care and science at the premier conference on inflammatory bowel disease (IBD).
bit.ly
October 2, 2025 at 2:06 PM
Join me & keynote speaker Dr. Florian Rieder at #CCCongress26, Jan. 22-24 in Vegas. @ibd-flomd.bsky.social does an outstanding job bridging #IBD basic science and clinical research, so this is sure to be a great talk Register by 10/21 & SAVE: 🔗 bit.ly/4m85s1N
#IBDsky #GIsky #Gastrosky
#IBDsky #GIsky #Gastrosky
So insightful to hear Dr. Marla Dubinsky summarize the the right drug at the right time in #IBD So many considerations for patients & clinicians #CCCongress26
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
January 23, 2026 at 10:59 PM
So insightful to hear Dr. Marla Dubinsky summarize the the right drug at the right time in #IBD So many considerations for patients & clinicians #CCCongress26
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
Grateful for Dr. Larry Kim’s leadership of the @amergastroassn.bsky.social 🎉 Beyond appreciative of the @crohnscolitisfdn.bsky.social incredible commitment to #IBD patients. Thank you Dr. Alan Moss (Chief Scientific Officer) for leading IBD scientific advancements at the Foundation🥹 #CCCongress26
January 23, 2026 at 5:01 PM
Grateful for Dr. Larry Kim’s leadership of the @amergastroassn.bsky.social 🎉 Beyond appreciative of the @crohnscolitisfdn.bsky.social incredible commitment to #IBD patients. Thank you Dr. Alan Moss (Chief Scientific Officer) for leading IBD scientific advancements at the Foundation🥹 #CCCongress26
As a #fistula patient myself, I know all too well the trauma that #IBD patients go through when living w/ #perianal disease. So valuable for the patient perspective & mental health recommendations to be shared & discussed at #CCCongress26
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
January 23, 2026 at 11:00 PM
As a #fistula patient myself, I know all too well the trauma that #IBD patients go through when living w/ #perianal disease. So valuable for the patient perspective & mental health recommendations to be shared & discussed at #CCCongress26
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
Live from #CCCongress26! Patient Reporter Ian Goldstein talks with Board of Trustees Chair Amber Backhaus about leadership, progress, and hope for everyone affected by IBD.
January 25, 2026 at 9:58 PM
Live from #CCCongress26! Patient Reporter Ian Goldstein talks with Board of Trustees Chair Amber Backhaus about leadership, progress, and hope for everyone affected by IBD.
Reflecting on my time at #CCCongress26 in Las Vegas💙As a #patient #advocate & someone living w/ #IBD it’s a privilege I don’t take lightly🥹To witness cutting-edge research🔬emerging treatments🧬 & the commitment of clinicians & researchers who care about patients is powerful💥
January 30, 2026 at 5:51 PM
Reflecting on my time at #CCCongress26 in Las Vegas💙As a #patient #advocate & someone living w/ #IBD it’s a privilege I don’t take lightly🥹To witness cutting-edge research🔬emerging treatments🧬 & the commitment of clinicians & researchers who care about patients is powerful💥
Key summaries of all of the latest advancements in treatment for both #CD and #UC at #CCCongress26 at #IBD 101, including bone marrow transplant success for CD (in Europe)🎉
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
January 22, 2026 at 7:04 PM
Key summaries of all of the latest advancements in treatment for both #CD and #UC at #CCCongress26 at #IBD 101, including bone marrow transplant success for CD (in Europe)🎉
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social
#CCCongress26 is underway in Las Vegas, bringing together experts, clinicians, and patients to advance care for people living with IBD. Stay tuned here for the latest updates, insights, and innovations from the Crohn’s & Colitis Congress 2026!
January 22, 2026 at 11:58 PM
#CCCongress26 is underway in Las Vegas, bringing together experts, clinicians, and patients to advance care for people living with IBD. Stay tuned here for the latest updates, insights, and innovations from the Crohn’s & Colitis Congress 2026!
Very excited about the 2026 Crohn’s & Colitis Congress® in Las Vegas, Jan. 22–24! Only a few days left of the Advanced discount period, closing Tuesday, October 21. #CCCongress26 is THE MEETING to learn and lead the future of IBD. Register ASAP 🔗bit.ly/4m85s1N!
October 17, 2025 at 7:19 PM
Very excited about the 2026 Crohn’s & Colitis Congress® in Las Vegas, Jan. 22–24! Only a few days left of the Advanced discount period, closing Tuesday, October 21. #CCCongress26 is THE MEETING to learn and lead the future of IBD. Register ASAP 🔗bit.ly/4m85s1N!
Missed #CCCongress26? We've got you covered.
Catch up on our reporting ⬇️
@crohnscolitisfdn.bsky.social
Catch up on our reporting ⬇️
@crohnscolitisfdn.bsky.social
January 26, 2026 at 3:32 PM
Missed #CCCongress26? We've got you covered.
Catch up on our reporting ⬇️
@crohnscolitisfdn.bsky.social
Catch up on our reporting ⬇️
@crohnscolitisfdn.bsky.social
Lastly, it has been wonderful chairing the Congress with my fellow co-chairs, Tina Ha & Jessica Allegretti. The planning for #CCCongress26 in #Vegas has already begun!
a sign that says welcome to fabulous las vegas
ALT: a sign that says welcome to fabulous las vegas
media.tenor.com
February 8, 2025 at 7:43 PM
Lastly, it has been wonderful chairing the Congress with my fellow co-chairs, Tina Ha & Jessica Allegretti. The planning for #CCCongress26 in #Vegas has already begun!
It’s Day 2 of #CCCongress26! From cutting-edge research to powerful patient stories, the Crohn’s & Colitis Congress is driving progress in IBD treatment and understanding.
January 23, 2026 at 11:06 PM
It’s Day 2 of #CCCongress26! From cutting-edge research to powerful patient stories, the Crohn’s & Colitis Congress is driving progress in IBD treatment and understanding.
📣 It’s #CrohnsColitisAwarenessWeek! Ready to take your IBD knowledge to the next level?
Join us at the 2026 Crohn’s & Colitis Congress
✨ Register by Dec. 9 & save up to $166
✨ Hotel deadline: Dec. 18
👉 crohnscolitiscongress.org?utm_medium=B...
#IBD #CCCongress26 #CrohnsColitisAwarenessWeek
Join us at the 2026 Crohn’s & Colitis Congress
✨ Register by Dec. 9 & save up to $166
✨ Hotel deadline: Dec. 18
👉 crohnscolitiscongress.org?utm_medium=B...
#IBD #CCCongress26 #CrohnsColitisAwarenessWeek
December 1, 2025 at 2:30 PM
📣 It’s #CrohnsColitisAwarenessWeek! Ready to take your IBD knowledge to the next level?
Join us at the 2026 Crohn’s & Colitis Congress
✨ Register by Dec. 9 & save up to $166
✨ Hotel deadline: Dec. 18
👉 crohnscolitiscongress.org?utm_medium=B...
#IBD #CCCongress26 #CrohnsColitisAwarenessWeek
Join us at the 2026 Crohn’s & Colitis Congress
✨ Register by Dec. 9 & save up to $166
✨ Hotel deadline: Dec. 18
👉 crohnscolitiscongress.org?utm_medium=B...
#IBD #CCCongress26 #CrohnsColitisAwarenessWeek
🧵1/5
I had a wonderful time at the Crohn's and Colitis Congress Revolutionizing #IBD Care Meeting in #LasVegas (1/22/26 - 1/24/26) listening to the latest scientific updates and catching up with my friends & colleagues!!
#CCCongress2026 #CCCongress26 #CCC2026 #CCC26
I had a wonderful time at the Crohn's and Colitis Congress Revolutionizing #IBD Care Meeting in #LasVegas (1/22/26 - 1/24/26) listening to the latest scientific updates and catching up with my friends & colleagues!!
#CCCongress2026 #CCCongress26 #CCC2026 #CCC26
February 22, 2026 at 4:25 PM
🧵1/5
I had a wonderful time at the Crohn's and Colitis Congress Revolutionizing #IBD Care Meeting in #LasVegas (1/22/26 - 1/24/26) listening to the latest scientific updates and catching up with my friends & colleagues!!
#CCCongress2026 #CCCongress26 #CCC2026 #CCC26
I had a wonderful time at the Crohn's and Colitis Congress Revolutionizing #IBD Care Meeting in #LasVegas (1/22/26 - 1/24/26) listening to the latest scientific updates and catching up with my friends & colleagues!!
#CCCongress2026 #CCCongress26 #CCC2026 #CCC26
People who identify as #LGBTQ+ face distinct and compounding challenges when living with IBD, according to a qualitative study. @crohnscolitisfdn.bsky.social @victorchedidmd.bsky.social #CCCongress26
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Focus Groups Expose Care Gaps for LGBTQ+ People Living With IBD
Patients report delayed diagnosis, ineffective treatment, and discrimination
www.medpagetoday.com
January 26, 2026 at 8:24 PM
People who identify as #LGBTQ+ face distinct and compounding challenges when living with IBD, according to a qualitative study. @crohnscolitisfdn.bsky.social @victorchedidmd.bsky.social #CCCongress26
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
GLP-1-based therapies may offer benefits in IBD that extend beyond their metabolic indication, according to two poster presentations at #CCCongress26.
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
GLP-1 Therapy May Offer Added Benefit in IBD Beyond Weight Loss
Real-world analyses suggest link to reduced steroid use, fewer hospital stays, lower mortality
www.medpagetoday.com
January 26, 2026 at 3:32 PM
GLP-1-based therapies may offer benefits in IBD that extend beyond their metabolic indication, according to two poster presentations at #CCCongress26.
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky
IV vs SC Vedolizumab for IBD | Docwire News
While intravenous and subcutaneous vedolizumab had largely similar safety and efficacy for IBD, there were a few key differences in outcomes.
www.docwirenews.com
February 10, 2026 at 1:27 AM
Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky
Prior exposure to anti-TNF therapy was associated with a lower risk of colectomy among patients receiving JAK inhibitor rescue therapy for acute severe ulcerative colitis, according to findings. #CCCongress26
https://www.medpagetoday.com/meetingcoverage/ccc/119560
https://www.medpagetoday.com/meetingcoverage/ccc/119560
Prior Biologic Use Tied to JAK Inhibitor Benefit in Ulcerative Colitis
In certain patients, JAK inhibitor rescue medications seem to be more effective, researcher says
www.medpagetoday.com
January 25, 2026 at 12:30 AM
Prior exposure to anti-TNF therapy was associated with a lower risk of colectomy among patients receiving JAK inhibitor rescue therapy for acute severe ulcerative colitis, according to findings. #CCCongress26
https://www.medpagetoday.com/meetingcoverage/ccc/119560
https://www.medpagetoday.com/meetingcoverage/ccc/119560
Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky
DBH Inhibitor for Ulcerative Colitis | Docwire News
In results from a phase 1b trial, dopamine beta-hydroxylase inhibitor, APL-1401, demonstrated early efficacy signals for patients with moderate-to-severe active ulcerative colitis.
www.docwirenews.com
February 7, 2026 at 2:32 AM
Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky
🧵3/5
...approaches for pediatric #Crohns disease!!
I also enjoyed sharing information about the newly launched
@childrensnational.bsky.social
#GrowthProgram (childrensnational.org/get-care/dep...) !!
#CCCongress2026 #CCCongress26 #SexDifferences #SexInScience #Bellagio #YearOfTheHorse
...approaches for pediatric #Crohns disease!!
I also enjoyed sharing information about the newly launched
@childrensnational.bsky.social
#GrowthProgram (childrensnational.org/get-care/dep...) !!
#CCCongress2026 #CCCongress26 #SexDifferences #SexInScience #Bellagio #YearOfTheHorse
February 22, 2026 at 4:28 PM
🧵3/5
...approaches for pediatric #Crohns disease!!
I also enjoyed sharing information about the newly launched
@childrensnational.bsky.social
#GrowthProgram (childrensnational.org/get-care/dep...) !!
#CCCongress2026 #CCCongress26 #SexDifferences #SexInScience #Bellagio #YearOfTheHorse
...approaches for pediatric #Crohns disease!!
I also enjoyed sharing information about the newly launched
@childrensnational.bsky.social
#GrowthProgram (childrensnational.org/get-care/dep...) !!
#CCCongress2026 #CCCongress26 #SexDifferences #SexInScience #Bellagio #YearOfTheHorse
Our IBD attendings presenting and having fun at #CCCongress2026 #CCCongress26. Thanks @crohnscolitisfdn.bsky.social !!!
January 24, 2026 at 2:39 PM
Our IBD attendings presenting and having fun at #CCCongress2026 #CCCongress26. Thanks @crohnscolitisfdn.bsky.social !!!
Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky
CATHARSIS Meets Measures for Continuation | Docwire News
With successful randomization, masking, and retention, the CATHARSIS trial has proved it warrants continuation.
www.docwirenews.com
February 5, 2026 at 2:28 AM
Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky
Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD.
#IBDSky #GISky
#IBDSky #GISky
Novel G9a-Inhibitor Shows Promise | Docwire News
According to data presented at the 2026 Crohn’s and Colitis Congress, ATH-063 showed preliminary potential with a favorable pharmacokinetics profile.
www.docwirenews.com
February 3, 2026 at 1:27 AM
Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD.
#IBDSky #GISky
#IBDSky #GISky
Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky
GLP-1 RAs and Crohn’s Disease | Docwire News
As reported at the 2026 Crohn’s and Colitis Congress, GLP-1 RAs are potentially beneficial as an adjunct to Crohn’s disease management for patients with overweight or obesity.
www.docwirenews.com
January 31, 2026 at 2:32 AM
Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky